Selected research
Market Outlook & Growth Opportunities
Global Cardiac AI-assisted Diagnosis Market Outlook and Growth Opportunities 2026
Market perspective
The global Cardiac AI-assisted Diagnosis market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.
The North America market for Cardiac AI-assisted Diagnosis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Cardiac AI-assisted Diagnosis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Cardiac AI-assisted Diagnosis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
In China, the Cardiac AI-assisted Diagnosis market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Major global companies in the Cardiac AI-assisted Diagnosis market include Lepu Medical, G K Healthcare, Sense Time, United Imaging, Infervision, Shukun, FOSUN AITROX, NANO-X and MyCardium AI, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.
This report provides an overview of the global Cardiac AI-assisted Diagnosis market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Cardiac AI-assisted Diagnosis and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Cardiac AI-assisted Diagnosis revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Cardiac AI-assisted Diagnosis market.
Cardiac AI-assisted Diagnosis Segment by Company
Lepu Medical
G K Healthcare
Sense Time
United Imaging
Infervision
Shukun
FOSUN AITROX
NANO-X
MyCardium AI
VUNO
Caption Care
UltraSight
Ultromics
Cleerly
Elucid
DiA Imaging Analysis
Koninklijke Philips N.V
Fujifilm
Cardiac AI-assisted Diagnosis Segment by Type
Cloud-based
On-Primes
Cardiac AI-assisted Diagnosis Segment by Application
Hospital
Clinic
Imaging Center
Cardiac AI-assisted Diagnosis Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Cardiac AI-assisted Diagnosis status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Cardiac AI-assisted Diagnosis key companies, revenue, market share, and recent developments.
3. To split the Cardiac AI-assisted Diagnosis breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Cardiac AI-assisted Diagnosis market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Cardiac AI-assisted Diagnosis significant trends, drivers, influence factors in global and regions.
6. To analyze Cardiac AI-assisted Diagnosis competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cardiac AI-assisted Diagnosis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Cardiac AI-assisted Diagnosis and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cardiac AI-assisted Diagnosis.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Cardiac AI-assisted Diagnosis industry.
Chapter 3: Detailed analysis of Cardiac AI-assisted Diagnosis company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Cardiac AI-assisted Diagnosis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Cardiac AI-assisted Diagnosis in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
More report detail
Tables and figures
Scope & coverage.
Types
- Cloud-based
- On-Primes
Applications
- Hospital
- Clinic
- Imaging Center
Companies covered
- Lepu Medical
- G K Healthcare
- Sense Time
- United Imaging
- Infervision
- Shukun
- FOSUN AITROX
- NANO-X
- MyCardium AI
- VUNO
- Caption Care
- UltraSight
- Ultromics
- Cleerly
- Elucid
- DiA Imaging Analysis
- Koninklijke Philips N.V
- Fujifilm
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Cardiac AI-assisted Diagnosis Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Cardiac AI-assisted Diagnosis Market Size (2021-2032)
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Cardiac AI-assisted Diagnosis Market Dynamics
- 2.1 Cardiac AI-assisted Diagnosis Industry Trends
- 2.2 Cardiac AI-assisted Diagnosis Industry Drivers
- 2.3 Cardiac AI-assisted Diagnosis Industry Opportunities and Challenges
- 2.4 Cardiac AI-assisted Diagnosis Industry Restraints
3 Cardiac AI-assisted Diagnosis Market by Company
- 3.1 Global Cardiac AI-assisted Diagnosis Company Revenue Ranking in 2025
- 3.2 Global Cardiac AI-assisted Diagnosis Revenue by Company (2021-2026)
- 3.3 Global Cardiac AI-assisted Diagnosis Company Ranking (2024-2026)
- 3.4 Global Cardiac AI-assisted Diagnosis Company Manufacturing Base and Headquarters
- 3.5 Global Cardiac AI-assisted Diagnosis Company Product Type and Application
- 3.6 Global Cardiac AI-assisted Diagnosis Company Establishment Date
- 3.7 Market Competitive Analysis
- 3.7.1 Global Cardiac AI-assisted Diagnosis Market Concentration Ratio (CR5 and HHI)
- 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.7.3 2025 Cardiac AI-assisted Diagnosis Tier 1, Tier 2, and Tier 3 Companies
- 3.8 Mergers and Acquisitions Expansion
4 Cardiac AI-assisted Diagnosis Market by Type
- 4.1 Cardiac AI-assisted Diagnosis Type Introduction
- 4.1.1 Cloud-based
- 4.1.2 On-Primes
- 4.2 Global Cardiac AI-assisted Diagnosis Sales Value by Type
- 4.2.1 Global Cardiac AI-assisted Diagnosis Sales Value by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Cardiac AI-assisted Diagnosis Sales Value by Type (2021-2032)
- 4.2.3 Global Cardiac AI-assisted Diagnosis Sales Value Share by Type (2021-2032)
5 Cardiac AI-assisted Diagnosis Market by Application
- 5.1 Cardiac AI-assisted Diagnosis Application Introduction
- 5.1.1 Hospital
- 5.1.2 Clinic
- 5.1.3 Imaging Center
- 5.2 Global Cardiac AI-assisted Diagnosis Sales Value by Application
- 5.2.1 Global Cardiac AI-assisted Diagnosis Sales Value by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Cardiac AI-assisted Diagnosis Sales Value by Application (2021-2032)
- 5.2.3 Global Cardiac AI-assisted Diagnosis Sales Value Share by Application (2021-2032)
6 Cardiac AI-assisted Diagnosis Regional Value Analysis
- 6.1 Global Cardiac AI-assisted Diagnosis Sales Value by Region: 2021 VS 2025 VS 2032
- 6.2 Global Cardiac AI-assisted Diagnosis Sales Value by Region (2021-2032)
- 6.2.1 Global Cardiac AI-assisted Diagnosis Sales Value by Region: 2021-2026
- 6.2.2 Global Cardiac AI-assisted Diagnosis Sales Value by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Cardiac AI-assisted Diagnosis Sales Value (2021-2032)
- 6.3.2 North America Cardiac AI-assisted Diagnosis Sales Value Share by Country, 2025 VS 2032
- 6.4 Europe
- 6.4.1 Europe Cardiac AI-assisted Diagnosis Sales Value (2021-2032)
- 6.4.2 Europe Cardiac AI-assisted Diagnosis Sales Value Share by Country, 2025 VS 2032
- 6.5 Asia-Pacific
- 6.5.1 Asia-Pacific Cardiac AI-assisted Diagnosis Sales Value (2021-2032)
- 6.5.2 Asia-Pacific Cardiac AI-assisted Diagnosis Sales Value Share by Country, 2025 VS 2032
- 6.6 South America
- 6.6.1 South America Cardiac AI-assisted Diagnosis Sales Value (2021-2032)
- 6.6.2 South America Cardiac AI-assisted Diagnosis Sales Value Share by Country, 2025 VS 2032
- 6.7 Middle East & Africa
- 6.7.1 Middle East & Africa Cardiac AI-assisted Diagnosis Sales Value (2021-2032)
- 6.7.2 Middle East & Africa Cardiac AI-assisted Diagnosis Sales Value Share by Country, 2025 VS 2032
7 Cardiac AI-assisted Diagnosis Country-level Value Analysis
- 7.1 Global Cardiac AI-assisted Diagnosis Sales Value by Country: 2021 VS 2025 VS 2032
- 7.2 Global Cardiac AI-assisted Diagnosis Sales Value by Country (2021-2032)
- 7.2.1 Global Cardiac AI-assisted Diagnosis Sales Value by Country (2021-2026)
- 7.2.2 Global Cardiac AI-assisted Diagnosis Sales Value by Country (2027-2032)
- 7.3 USA
- 7.3.1 USA Cardiac AI-assisted Diagnosis Sales Value Growth Rate (2021-2032)
- 7.3.2 USA Cardiac AI-assisted Diagnosis Sales Value Share by Type, 2025 VS 2032
- 7.3.3 USA Cardiac AI-assisted Diagnosis Sales Value Share by Application, 2025 VS 2032
- 7.4 Canada
- 7.4.1 Canada Cardiac AI-assisted Diagnosis Sales Value Growth Rate (2021-2032)
- 7.4.2 Canada Cardiac AI-assisted Diagnosis Sales Value Share by Type, 2025 VS 2032
- 7.4.3 Canada Cardiac AI-assisted Diagnosis Sales Value Share by Application, 2025 VS 2032
- 7.5 Mexico
- 7.5.1 Mexico Cardiac AI-assisted Diagnosis Sales Value Growth Rate (2021-2032)
- 7.5.2 Mexico Cardiac AI-assisted Diagnosis Sales Value Share by Type, 2025 VS 2032
- 7.5.3 Mexico Cardiac AI-assisted Diagnosis Sales Value Share by Application, 2025 VS 2032
- 7.6 Germany
- 7.6.1 Germany Cardiac AI-assisted Diagnosis Sales Value Growth Rate (2021-2032)
- 7.6.2 Germany Cardiac AI-assisted Diagnosis Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Germany Cardiac AI-assisted Diagnosis Sales Value Share by Application, 2025 VS 2032
- 7.7 France
- 7.7.1 France Cardiac AI-assisted Diagnosis Sales Value Growth Rate (2021-2032)
- 7.7.2 France Cardiac AI-assisted Diagnosis Sales Value Share by Type, 2025 VS 2032
- 7.7.3 France Cardiac AI-assisted Diagnosis Sales Value Share by Application, 2025 VS 2032
- 7.8 U.K.
- 7.8.1 U.K. Cardiac AI-assisted Diagnosis Sales Value Growth Rate (2021-2032)
- 7.8.2 U.K. Cardiac AI-assisted Diagnosis Sales Value Share by Type, 2025 VS 2032
- 7.8.3 U.K. Cardiac AI-assisted Diagnosis Sales Value Share by Application, 2025 VS 2032
- 7.9 Italy
- 7.9.1 Italy Cardiac AI-assisted Diagnosis Sales Value Growth Rate (2021-2032)
- 7.9.2 Italy Cardiac AI-assisted Diagnosis Sales Value Share by Type, 2025 VS 2032
- 7.9.3 Italy Cardiac AI-assisted Diagnosis Sales Value Share by Application, 2025 VS 2032
- 7.10 Spain
- 7.10.1 Spain Cardiac AI-assisted Diagnosis Sales Value Growth Rate (2021-2032)
- 7.10.2 Spain Cardiac AI-assisted Diagnosis Sales Value Share by Type, 2025 VS 2032
- 7.10.3 Spain Cardiac AI-assisted Diagnosis Sales Value Share by Application, 2025 VS 2032
- 7.11 Russia
- 7.11.1 Russia Cardiac AI-assisted Diagnosis Sales Value Growth Rate (2021-2032)
- 7.11.2 Russia Cardiac AI-assisted Diagnosis Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Russia Cardiac AI-assisted Diagnosis Sales Value Share by Application, 2025 VS 2032
- 7.12 Netherlands
- 7.12.1 Netherlands Cardiac AI-assisted Diagnosis Sales Value Growth Rate (2021-2032)
- 7.12.2 Netherlands Cardiac AI-assisted Diagnosis Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Netherlands Cardiac AI-assisted Diagnosis Sales Value Share by Application, 2025 VS 2032
- 7.13 Nordic Countries
- 7.13.1 Nordic Countries Cardiac AI-assisted Diagnosis Sales Value Growth Rate (2021-2032)
- 7.13.2 Nordic Countries Cardiac AI-assisted Diagnosis Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Nordic Countries Cardiac AI-assisted Diagnosis Sales Value Share by Application, 2025 VS 2032
- 7.14 China
- 7.14.1 China Cardiac AI-assisted Diagnosis Sales Value Growth Rate (2021-2032)
- 7.14.2 China Cardiac AI-assisted Diagnosis Sales Value Share by Type, 2025 VS 2032
- 7.14.3 China Cardiac AI-assisted Diagnosis Sales Value Share by Application, 2025 VS 2032
- 7.15 Japan
- 7.15.1 Japan Cardiac AI-assisted Diagnosis Sales Value Growth Rate (2021-2032)
- 7.15.2 Japan Cardiac AI-assisted Diagnosis Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Japan Cardiac AI-assisted Diagnosis Sales Value Share by Application, 2025 VS 2032
- 7.16 South Korea
- 7.16.1 South Korea Cardiac AI-assisted Diagnosis Sales Value Growth Rate (2021-2032)
- 7.16.2 South Korea Cardiac AI-assisted Diagnosis Sales Value Share by Type, 2025 VS 2032
- 7.16.3 South Korea Cardiac AI-assisted Diagnosis Sales Value Share by Application, 2025 VS 2032
- 7.17 India
- 7.17.1 India Cardiac AI-assisted Diagnosis Sales Value Growth Rate (2021-2032)
- 7.17.2 India Cardiac AI-assisted Diagnosis Sales Value Share by Type, 2025 VS 2032
- 7.17.3 India Cardiac AI-assisted Diagnosis Sales Value Share by Application, 2025 VS 2032
- 7.18 Australia
- 7.18.1 Australia Cardiac AI-assisted Diagnosis Sales Value Growth Rate (2021-2032)
- 7.18.2 Australia Cardiac AI-assisted Diagnosis Sales Value Share by Type, 2025 VS 2032
- 7.18.3 Australia Cardiac AI-assisted Diagnosis Sales Value Share by Application, 2025 VS 2032
- 7.19 Southeast Asia
- 7.19.1 Southeast Asia Cardiac AI-assisted Diagnosis Sales Value Growth Rate (2021-2032)
- 7.19.2 Southeast Asia Cardiac AI-assisted Diagnosis Sales Value Share by Type, 2025 VS 2032
- 7.19.3 Southeast Asia Cardiac AI-assisted Diagnosis Sales Value Share by Application, 2025 VS 2032
- 7.20 Brazil
- 7.20.1 Brazil Cardiac AI-assisted Diagnosis Sales Value Growth Rate (2021-2032)
- 7.20.2 Brazil Cardiac AI-assisted Diagnosis Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Brazil Cardiac AI-assisted Diagnosis Sales Value Share by Application, 2025 VS 2032
- 7.21 Argentina
- 7.21.1 Argentina Cardiac AI-assisted Diagnosis Sales Value Growth Rate (2021-2032)
- 7.21.2 Argentina Cardiac AI-assisted Diagnosis Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Argentina Cardiac AI-assisted Diagnosis Sales Value Share by Application, 2025 VS 2032
- 7.22 Chile
- 7.22.1 Chile Cardiac AI-assisted Diagnosis Sales Value Growth Rate (2021-2032)
- 7.22.2 Chile Cardiac AI-assisted Diagnosis Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Chile Cardiac AI-assisted Diagnosis Sales Value Share by Application, 2025 VS 2032
- 7.23 Colombia
- 7.23.1 Colombia Cardiac AI-assisted Diagnosis Sales Value Growth Rate (2021-2032)
- 7.23.2 Colombia Cardiac AI-assisted Diagnosis Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Colombia Cardiac AI-assisted Diagnosis Sales Value Share by Application, 2025 VS 2032
- 7.24 Peru
- 7.24.1 Peru Cardiac AI-assisted Diagnosis Sales Value Growth Rate (2021-2032)
- 7.24.2 Peru Cardiac AI-assisted Diagnosis Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Peru Cardiac AI-assisted Diagnosis Sales Value Share by Application, 2025 VS 2032
- 7.25 Saudi Arabia
- 7.25.1 Saudi Arabia Cardiac AI-assisted Diagnosis Sales Value Growth Rate (2021-2032)
- 7.25.2 Saudi Arabia Cardiac AI-assisted Diagnosis Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Saudi Arabia Cardiac AI-assisted Diagnosis Sales Value Share by Application, 2025 VS 2032
- 7.26 Israel
- 7.26.1 Israel Cardiac AI-assisted Diagnosis Sales Value Growth Rate (2021-2032)
- 7.26.2 Israel Cardiac AI-assisted Diagnosis Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Israel Cardiac AI-assisted Diagnosis Sales Value Share by Application, 2025 VS 2032
- 7.27 UAE
- 7.27.1 UAE Cardiac AI-assisted Diagnosis Sales Value Growth Rate (2021-2032)
- 7.27.2 UAE Cardiac AI-assisted Diagnosis Sales Value Share by Type, 2025 VS 2032
- 7.27.3 UAE Cardiac AI-assisted Diagnosis Sales Value Share by Application, 2025 VS 2032
- 7.28 Turkey
- 7.28.1 Turkey Cardiac AI-assisted Diagnosis Sales Value Growth Rate (2021-2032)
- 7.28.2 Turkey Cardiac AI-assisted Diagnosis Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Turkey Cardiac AI-assisted Diagnosis Sales Value Share by Application, 2025 VS 2032
- 7.29 Iran
- 7.29.1 Iran Cardiac AI-assisted Diagnosis Sales Value Growth Rate (2021-2032)
- 7.29.2 Iran Cardiac AI-assisted Diagnosis Sales Value Share by Type, 2025 VS 2032
- 7.29.3 Iran Cardiac AI-assisted Diagnosis Sales Value Share by Application, 2025 VS 2032
- 7.30 Egypt
- 7.30.1 Egypt Cardiac AI-assisted Diagnosis Sales Value Growth Rate (2021-2032)
- 7.30.2 Egypt Cardiac AI-assisted Diagnosis Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Egypt Cardiac AI-assisted Diagnosis Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 Lepu Medical
- 8.1.1 Lepu Medical Company Information
- 8.1.2 Lepu Medical Business Overview
- 8.1.3 Lepu Medical Cardiac AI-assisted Diagnosis Revenue and Gross Margin (2021-2026)
- 8.1.4 Lepu Medical Cardiac AI-assisted Diagnosis Product Portfolio
- 8.1.5 Lepu Medical Recent Developments
- 8.2 G K Healthcare
- 8.2.1 G K Healthcare Company Information
- 8.2.2 G K Healthcare Business Overview
- 8.2.3 G K Healthcare Cardiac AI-assisted Diagnosis Revenue and Gross Margin (2021-2026)
- 8.2.4 G K Healthcare Cardiac AI-assisted Diagnosis Product Portfolio
- 8.2.5 G K Healthcare Recent Developments
- 8.3 Sense Time
- 8.3.1 Sense Time Company Information
- 8.3.2 Sense Time Business Overview
- 8.3.3 Sense Time Cardiac AI-assisted Diagnosis Revenue and Gross Margin (2021-2026)
- 8.3.4 Sense Time Cardiac AI-assisted Diagnosis Product Portfolio
- 8.3.5 Sense Time Recent Developments
- 8.4 United Imaging
- 8.4.1 United Imaging Company Information
- 8.4.2 United Imaging Business Overview
- 8.4.3 United Imaging Cardiac AI-assisted Diagnosis Revenue and Gross Margin (2021-2026)
- 8.4.4 United Imaging Cardiac AI-assisted Diagnosis Product Portfolio
- 8.4.5 United Imaging Recent Developments
- 8.5 Infervision
- 8.5.1 Infervision Company Information
- 8.5.2 Infervision Business Overview
- 8.5.3 Infervision Cardiac AI-assisted Diagnosis Revenue and Gross Margin (2021-2026)
- 8.5.4 Infervision Cardiac AI-assisted Diagnosis Product Portfolio
- 8.5.5 Infervision Recent Developments
- 8.6 Shukun
- 8.6.1 Shukun Company Information
- 8.6.2 Shukun Business Overview
- 8.6.3 Shukun Cardiac AI-assisted Diagnosis Revenue and Gross Margin (2021-2026)
- 8.6.4 Shukun Cardiac AI-assisted Diagnosis Product Portfolio
- 8.6.5 Shukun Recent Developments
- 8.7 FOSUN AITROX
- 8.7.1 FOSUN AITROX Company Information
- 8.7.2 FOSUN AITROX Business Overview
- 8.7.3 FOSUN AITROX Cardiac AI-assisted Diagnosis Revenue and Gross Margin (2021-2026)
- 8.7.4 FOSUN AITROX Cardiac AI-assisted Diagnosis Product Portfolio
- 8.7.5 FOSUN AITROX Recent Developments
- 8.8 NANO-X
- 8.8.1 NANO-X Company Information
- 8.8.2 NANO-X Business Overview
- 8.8.3 NANO-X Cardiac AI-assisted Diagnosis Revenue and Gross Margin (2021-2026)
- 8.8.4 NANO-X Cardiac AI-assisted Diagnosis Product Portfolio
- 8.8.5 NANO-X Recent Developments
- 8.9 MyCardium AI
- 8.9.1 MyCardium AI Company Information
- 8.9.2 MyCardium AI Business Overview
- 8.9.3 MyCardium AI Cardiac AI-assisted Diagnosis Revenue and Gross Margin (2021-2026)
- 8.9.4 MyCardium AI Cardiac AI-assisted Diagnosis Product Portfolio
- 8.9.5 MyCardium AI Recent Developments
- 8.10 VUNO
- 8.10.1 VUNO Company Information
- 8.10.2 VUNO Business Overview
- 8.10.3 VUNO Cardiac AI-assisted Diagnosis Revenue and Gross Margin (2021-2026)
- 8.10.4 VUNO Cardiac AI-assisted Diagnosis Product Portfolio
- 8.10.5 VUNO Recent Developments
- 8.11 Caption Care
- 8.11.1 Caption Care Company Information
- 8.11.2 Caption Care Business Overview
- 8.11.3 Caption Care Cardiac AI-assisted Diagnosis Revenue and Gross Margin (2021-2026)
- 8.11.4 Caption Care Cardiac AI-assisted Diagnosis Product Portfolio
- 8.11.5 Caption Care Recent Developments
- 8.12 UltraSight
- 8.12.1 UltraSight Company Information
- 8.12.2 UltraSight Business Overview
- 8.12.3 UltraSight Cardiac AI-assisted Diagnosis Revenue and Gross Margin (2021-2026)
- 8.12.4 UltraSight Cardiac AI-assisted Diagnosis Product Portfolio
- 8.12.5 UltraSight Recent Developments
- 8.13 Ultromics
- 8.13.1 Ultromics Company Information
- 8.13.2 Ultromics Business Overview
- 8.13.3 Ultromics Cardiac AI-assisted Diagnosis Revenue and Gross Margin (2021-2026)
- 8.13.4 Ultromics Cardiac AI-assisted Diagnosis Product Portfolio
- 8.13.5 Ultromics Recent Developments
- 8.14 Cleerly
- 8.14.1 Cleerly Company Information
- 8.14.2 Cleerly Business Overview
- 8.14.3 Cleerly Cardiac AI-assisted Diagnosis Revenue and Gross Margin (2021-2026)
- 8.14.4 Cleerly Cardiac AI-assisted Diagnosis Product Portfolio
- 8.14.5 Cleerly Recent Developments
- 8.15 Elucid
- 8.15.1 Elucid Company Information
- 8.15.2 Elucid Business Overview
- 8.15.3 Elucid Cardiac AI-assisted Diagnosis Revenue and Gross Margin (2021-2026)
- 8.15.4 Elucid Cardiac AI-assisted Diagnosis Product Portfolio
- 8.15.5 Elucid Recent Developments
- 8.16 DiA Imaging Analysis
- 8.16.1 DiA Imaging Analysis Company Information
- 8.16.2 DiA Imaging Analysis Business Overview
- 8.16.3 DiA Imaging Analysis Cardiac AI-assisted Diagnosis Revenue and Gross Margin (2021-2026)
- 8.16.4 DiA Imaging Analysis Cardiac AI-assisted Diagnosis Product Portfolio
- 8.16.5 DiA Imaging Analysis Recent Developments
- 8.17 Koninklijke Philips N.V
- 8.17.1 Koninklijke Philips N.V Company Information
- 8.17.2 Koninklijke Philips N.V Business Overview
- 8.17.3 Koninklijke Philips N.V Cardiac AI-assisted Diagnosis Revenue and Gross Margin (2021-2026)
- 8.17.4 Koninklijke Philips N.V Cardiac AI-assisted Diagnosis Product Portfolio
- 8.17.5 Koninklijke Philips N.V Recent Developments
- 8.18 Fujifilm
- 8.18.1 Fujifilm Company Information
- 8.18.2 Fujifilm Business Overview
- 8.18.3 Fujifilm Cardiac AI-assisted Diagnosis Revenue and Gross Margin (2021-2026)
- 8.18.4 Fujifilm Cardiac AI-assisted Diagnosis Product Portfolio
- 8.18.5 Fujifilm Recent Developments
9 Concluding Insights
10 Appendix
- 10.1 Reasons for Doing This Study
- 10.2 Research Methodology
- 10.3 Research Process
- 10.4 Authors List of This Report
- 10.5 Data Source
- 10.5.1 Secondary Sources
- 10.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst